Creative BioMart to Present at
                        BIO-Europe Spring Creative BioMart to Present at AACR Annual Meeting|Apr. 5-10, 2024|Booth #2953

Recombinant Rhesus Monkey TNFRSF18 Protein, hIgG4-tagged

Cat.No. : TNFRSF18-1787R
Product Overview : Recombinant Rhesus monkey TNFRSF18 Protein (XP_014971033 ( aa.26-162)) was expressed in human HEK293 cells with hIgG4 tag.
  • Specification
  • Gene Information
  • Related Products
Description : Receptor for TNFSF18. Seems to be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. Mediated NF-kappa-B activation via the TRAF2/NIK pathway.
Source : HEK293
Species : Rhesus monkey
Tag : hIgG4
Form : PBS, pH7.4.
Purity : > 95 %
Applications : ELISA; WB; Immunogen
Storage : -80 centigrade, Avoid freeze/thaw cycle.
Concentration : 1 mg/mL
Gene Name : TNFRSF18 TNF receptor superfamily member 18 [ Macaca mulatta (Rhesus monkey) ]
Official Symbol : TNFRSF18
Synonyms : TNFRSF18; tumor necrosis factor receptor superfamily; member 18; tumor necrosis factor receptor superfamily member 18; AITR; CD357; GITR; activation-inducible TNFR family receptor; glucocorticoid-induced TNFR-related protein; TNF receptor superfamily activation-inducible protein; GITR-D;
Gene ID : 699559
mRNA Refseq : XM_015115547.1
Protein Refseq : XP_014971033

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (5)

Ask a question
What are some current clinical trials involving TNFRSF18-targeted therapies in cancer treatment? 12/20/2022

Clinical trials are investigating TNFRSF18 agonists, such as monoclonal antibodies, in combination with other cancer treatments in various cancer types.

Are there any approved TNFRSF18-targeted therapies for cancer treatment? 06/29/2019

As of my knowledge cutoff date in January 2022, there were no approved TNFRSF18-targeted therapies for cancer. However, this may have changed since then.

Are there potential side effects associated with TNFRSF18-targeted therapies? 12/30/2018

Side effects may include immune-related adverse events, similar to those seen with other immunotherapies, and can range from mild to severe.

How can TNFRSF18-targeted therapies potentially improve cancer outcomes? 05/05/2018

TNFRSF18-targeted therapies may enhance the body's immune response against cancer cells, leading to better tumor control and improved patient outcomes.

Can TNFRSF18-targeted therapies be used in combination with other immunotherapies? 05/20/2016

Yes, combination therapies involving TNFRSF18 agonists and other immunotherapies are under investigation to improve treatment efficacy.

Customer Reviews (3)

Write a review
Reviews
12/20/2021

    This flexibility enables researchers like myself to tailor TNFRSF18 protein experiments to our unique needs, enhancing the reliability and relevance of the obtained results.

    03/05/2020

      Their commitment to delivering exceptional products and assisting with any challenges that may arise ensures a successful and rewarding experimental journey.

      10/01/2017

        The TNFRSF18 protein offered by the manufacturer is of exceptional quality, and it meets the rigorous standards necessary for my experimental needs.

        Ask a Question for All TNFRSF18 Products

        Required fields are marked with *

        My Review for All TNFRSF18 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /

        Stay Updated on the Latest Bioscience Trends